| Literature DB >> 27223084 |
Huiquan Liu1, Yaqun Zhou2, Qingquan Liu3, Guangqin Xiao4, Bangyan Wang1, Weijuan Li1, Dawei Ye1, Shiying Yu1.
Abstract
Single nucleotide polymorphisms (SNPs) in MicroRNAs (miRNAs) are involved in the mechanism of carcinogenesis. Several studies have evaluated the association of rs4919510 SNP in miR-608 with cancer susceptibility in different types of cancer, with inconclusive outcomes. To obtain a more precise estimation, we carried out this meta-analysis through systematic retrieval from the PubMed and Embase database. A total of 10 case-control studies were analyzed with 6,000 cases and 7,664 controls. The results showed that 4919510 SNP in miR-608 was significantly associated with decreased cancer risk only in recessive model (CC vs. GG+GC: OR=0.89, 95% CI: 0.82-0.97, P=0.009). By further stratified analysis, we found that rs4919510 SNP had some relationship with decreased cancer risk in both homozygote model (CC vs. GG: OR=0.59, 95% CI: 0.36-0.96, P=0.034) and dominant model (CG+ CC vs. GG: OR=0.60, 95% CI: 0.37-0.98, P=0.042) in Caucasians but no relationship in any genetic model in Asians. These results indicated that miR-608 rs4919510 polymorphism may contribute to the decreased cancer susceptibility and could be a promising target to forecast cancer risk for clinical practice. However, to further confirm these results, well-designed large scale case-control studies are needed in the future.Entities:
Keywords: cancer risk; meta-analysis; miR-608; polymorphism; rs4919510
Mesh:
Substances:
Year: 2017 PMID: 27223084 PMCID: PMC5514889 DOI: 10.18632/oncotarget.9509
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Study flow chart for the process of selecting the eligible publications
Characteristics of studies in the meta-analysis
| Author | Year | country | Ethnicity | Cancer type | Genotyping | Source of controls | Cases(n) | Controls(n) | P value for HWE h | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | GG | GC | CC | Total | GG | GC | CC | ||||||||
| Dong | 2015 | China | Asian | Thyroid tumor | MassArray | HB f | 369 | 136 | 186 | 47 | 751 | 279 | 370 | 102 | 0.494 |
| Zhang | 2015 | China | Asian | ESCC b | SNaPshot | PB g | 738 | 217 | 384 | 137 | 882 | 291 | 440 | 151 | 0.784 |
| Yin | 2015 | China | Asian | Lung cancer | Taqman | HB | 258 | 65 | 140 | 53 | 310 | 96 | 152 | 62 | 0.992 |
| Wei | 2015 | China | Asian | Thyroid tumor | MassArray | PB | 824 | 266 | 428 | 130 | 1031 | 326 | 503 | 202 | 0.950 |
| Qiu | 2015 | China | Asian | SCCHN c | TaqMan | PB | 906 | 255 | 460 | 191 | 1072 | 254 | 532 | 286 | 0.977 |
| Wang | 2014 | China | Asian | HCC d | MassArray | HB | 993 | 304 | 500 | 189 | 992 | 318 | 497 | 177 | 0.775 |
| Huang | 2012 | China | Asian | Breast cancer | SNPstream | PB | 1118 | 381 | 545 | 192 | 1417 | 456 | 684 | 277 | 0.776 |
| Kupcinskas | 2014 | Lithuania | Caucasian | Gastric cancer | RT-PCR | HB | 363 | 25 | 88 | 250 | 350 | 13 | 86 | 251 | 0.275 |
| Kupcinskas | 2014 | Lithuania | Caucasian | CRC e | RT-PCR | HB | 192 | 7 | 47 | 138 | 426 | 12 | 96 | 318 | 0.364 |
| Ryan | 2012 | USA | Mixed races a | CRC | Taqman | PB/HB | 239 | 19 | 96 | 124 | 433 | 36 | 166 | 231 | 0.729 |
a Caucasian and African Americans; b ESCC esophageal squamous cell carcinoma; c SCCHN squamous cell carcinoma of the head and neck; d HCC hepatocellular carcinoma; e CRC colorectal cancer; f HB hospital-based; g PB population-based; h HWE Hardy-Weinberg equilibrium.
The result of meta-analysis for various genotype models
| Test of Association | P Value for heterogeneity | I2 (%) | ||||
|---|---|---|---|---|---|---|
| OR (95%CI)b | Z | P Value | ||||
| Totala | CC vs. GG | 0.90 (0.77,1.06) | 1.23 | 0.219c | 0.031 | 51.1% |
| CG vs. GG | 1.01 (0.93,1.10) | 0.31 | 0.754d | 0.361 | 8.8% | |
| CG+CC vs.GG | 0.98 (0.88,1.10) | 0.28 | 0.776c | 0.093 | 39.7% | |
| GG+GC vs.CC | 0.89 (0.82,0.97) | 2.61 | 0.009d | 0.268 | 19.0% | |
| Asian | CC vs. GG | 0.93 (0.77,1.11) | 0.81 | 0.418c | 0.016 | 61.6% |
| CG vs. GG | 1.02 (0.94,1.11) | 0.51 | 0.610d | 0.353 | 9.9% | |
| CG+CC vs.GG | 1.00 (0.89,1.12) | 0.01 | 0.988c | 0.079 | 47.0% | |
| GG+GC vs.CC | 0.90 (0.79,1.03) | 1.51 | 0.130c | 0.090 | 45.3% | |
| Caucasian | CC vs. GG | 0.59 (0.36,0.96) | 2.12 | 0.034d | 0.832 | 0.0% |
| CG vs. GG | 0.65 (0.39,1.09) | 1.63 | 0.103d | 0.727 | 0.0% | |
| CG+CC vs.GG | 0.60 (0.37,0.98) | 2.03 | 0.042d | 0.802 | 0.0% | |
| GG+GC vs.CC | 0.84 (0.68,1.04) | 1.56 | 0.118d | 0.876 | 0.0% | |
aContrasts including homozygote model (CC vs. GG), heterozygote model (CG vs. GG), dominant model (CG+ CC vs. GG) and recessive model (CC vs. GG+GC) respectively.
bR odds ratio, CI confidence interval.
cP-value for significance under random-effects model.
dP-value for significance under fixed-effects model.
Figure 2Overall meta-analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in recessive model (CC vs. GG+GC)
Figure 3Subgroup analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in Caucasians
A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).
Figure 4Subgroup analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in Asians
A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).
Figure 5Funnel plot for publication bias test
A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).
Figure 6Begg's funnel plot for publication bias test
A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).
Figure 7The influence of individual studies on the overall OR in recessive model (CC vs. GG+GC)